Introduction:
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.